Matrix metalloproteinase-2 and -9 in bile as a marker of liver metastasis in colorectal cancer

Biochemical and Biophysical Research Communications

Volumn 288, Issue 1, 2001, Pages 212-216

  Okada, Norimichi ^a,b   Ishida, Hideyuki ^b   Murata, Nobuo ^b   Hashimoto, Daijo ^b   Seyama, Yousuke ^a   Kubota, Shunichiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Bile; Colorectal cancer; Metastasis; MMP 2; MMP 9

Indexed keywords

ENZYME PRECURSOR; GELATINASE A; GELATINASE B;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BILE LEVEL; CANCER DIAGNOSIS; CANCER INVASION; COLORECTAL CANCER; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DISEASE MARKER; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; ZYMOGRAPHY;

EID: 0035913972     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.2001.5741     Document Type: Article

References (30)

1. Matrix metalloprteinases: Molecular aspects of their roles in tumour invasion and metastasis
2. Matrix metalloproteinases
3. Matrix metalloproteinases
4. Identification and characterization of human endometase (matrix metalloproteinase-26) from endometrial tumor
5. Matrix metalloproteinases: Biologic activity and clinical implications
6. Metalloproteinases and cancer invasion
7. Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas
8. Expression of MMP-7 (PUMP-1) mRNA in human colorectal cancers
9. Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer
10. Colocalisation of matrix metalloproteinase-9 mRNA and protein in human colorectal cancer stromal cells
11. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9
12. Stromal expression of 72kDa type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia
13. Matrix metalloproteinase 2 (MMP-2) and matrix metalloproteinase 9 (MMP-9) type IV collagenases in colorectal cancer
14. Increased type IV collagen-degrading activity in metastases originating from primary tumors of the human colon
15. Unique activation of matrix metalloproteinase-9 within human liver metastasis from colorectal cancer
16. Gelatinase (MMP-2 and 9) expression in gastrointestinal malignancy
17. Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis
18. Proteolysis in colorectal cancer
19. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging
20. Significance of coexression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma
21. r 92 000 type IV collagenase is increased in plasma of proteins with colon cancer and breast cancer
22. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues: Clinical and experimental applications
23. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer
24. The expression of MMP-2 and TIMP-2 in patients with primary colorectal adenocarcinoma: Correlation with liver metastasis
25. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer
26. Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates
27. Ornithine dacarboxylase overexpression in mouse 10T1/2 fibroblasts: Cellular transformation and invasion
28. Anti-alpha3 integrin antibody induces the activated form of matrix metalloprotease-2 (MMP-2) with concomitant stimulation of invasion through matrigel by human rhabdomyosarcoma cells
29. Quantitative zymography: Detection of picogram quantities of gelatinases
30. Role of the liver in clearance and excretion of circulating carcinoembryonic antigen (CEA)